|
“10-year Biochemical (prostate specific antigen) Control of Prostate Cancer with 125-I Brachytherapy.”
Peter D. Grimm, D.O., John C. Blasko, M.D., John E. Sylvester, M.D.,Robert M. Meier, M.D., and William Cavanagh, B.S. Int. J. Radiation Oncology Biol. Phys., Vol. 51, No. 1, 2001
This study strived to report 10-year
biochemical outcomes for patients who received I-125
brachytherapy
as an early stage prostate
cancer treatment from January 1988 and December
1990. Out of 126 patients only 125 comprised the basis
for this study; one patient could not be located to
follow-up. All patients included in the study had a
prostate cancer stage of T1-T2b. Estimates of PSA progression-free
survival were gathered from Kaplan-Meier on the basis
of two consecutive elevations of PSA. For low risk patients
at 10 years following the procedure the overall PSA
progression-free
survival rate was 87%. Those followed more than
seven years included 59 patients, 51 (86%) had PSA levels
less than .5ng/mL, and 48 (81%) had PSA levels less
than .2ng/mL. This study analyzed another cohort in
1986-1987 and compared the progression-free survival
rates of both groups. They have found that as the technique
matures an improvement in biochemical control results.
“Radioactive sources embedded in suture are associated with improved postimplant dosimetry in men treated with prostate brachytherapy”
William Robert Lee, Allan F. deGuzman, Shannon K. Tomlinson, David L. McCullough.
Radiotherapy and Oncology, Journal of the European society for Therapeutic Radiology and Oncology 65 (2002) 123-127
This study wanted to research whether the use of sources embedded in suture (SES) would affect certain measurements of the implant. Under this trial doctors studied two groups of brachytherapy patients and compared their outcomes. One group consisted of 20 patients treated with loose sources (LS) between September 1999 and April 2000. The other group consisted of 20 patients treated with SES between May 2000 and February 2001. In order to calculate the dosimetric quantifiers of the implant a tomography scan was performed one month preceding all brachytherapy treatments. Results were in favor of SES. When this method was compared to LS, the prostate gland had decreased more in patients treated with SES. Although the total activity and activity per seed were similar for both groups, the activity per unit volume was slightly higher for those who received SES. Other advantages of the SES group include improved prostate radiation measurements and general V100 rate at 94.10%, compared to 86.54% for those treated with LS.
“Reduction of Radioactive Seed Embolization to the Lung Following Prostate Brachytherapy”
Elizabeth M. Tappen, M.D., John C. Blasko, M.D., Peter D. Grimm, D.O., Haakon Ragde, M.D., Ray Luse, M.S., Stephanie Clifford, John Sylvester, M.D., and Thomas W. Griffin, M.D. Int. J. Radiation Oncology Biol. Phys., Vol. 42, No. 5, pp. 1063-1067, 1998
This study focused on analyzing the incidence and possible negative effects of seed migration. Between January 1 and December 31, 1995, 290 consecutive patients were treated with permanent radioactive seed brachytherapy for prostate cancer. Of that group, 154 patients received I-125 and 136 patients received Pd-103. With the exception of one, all patients had routine chest radiographs prior to the implant, leaving 289 patients to evaluate. With respect to the entire group 5.9% exhibited a radioactive seed pulmonary rate with no reported acute symptoms. Those who were implanted with free seeds consisted of 146 patients and those with linked seeds embedded in a vicryl suture consisted of 143 patients. For free seed implants, 11% experienced a radioactive seed embolization rate and .7% of linked seed implants experienced the same. This statistic demonstrates that linked seeds embedded in vicryl sutures under this procedure reduced the occurrence of pulmonary seed embolization.
|
|
|
